Navigation Links
Yale test detects early stage ovarian cancer with 99 percent accuracy
Date:2/12/2008

Researchers at Yale School of Medicine have developed a blood test with enough sensitivity and specificity to detect early stage ovarian cancer with 99 percent accuracy.

Results of this new study are published in the February 15 issue of the journal Clinical Cancer Research. The results build on work done by the same Yale group in 2005 showing 95 percent effectiveness of a blood test using four proteins.

The ability to recognize almost 100 percent of new tumors will have a major impact on the high death rates of this cancer, said Mor. We hope this test will become the standard of care for women having routine examinations.

Epithelial ovarian cancer is the leading cause of gynecologic cancer deaths in the United States and three times more lethal than breast cancer. It is usually not diagnosed until its advanced stages and has come to be known as the silent killer.

This new phase II clinical trial led by Gil Mor, M.D., associate professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale, included 500 patients; 350 healthy controls and 150 ovarian cancer patients. Mor and colleagues validated the previous research and used a new platform called multiplex technology to simplify the test into one single reaction using very small amounts of serum from the blood. The new platform uses six protein biomarkers instead of four, increasing the specificity of the test from 95 to 99.4 percent. The team looked for the presence of specific proteins and quantified the concentration of those proteins in the blood.

The Early Detection Research Network (EDRN) of the National Cancer Institute (NCI) independently evaluated the results of the test.

This is the most sensitive and specific test currently available, said Mor. Previous tests recognized 15 to 20 percent of new tumors. Proteins from the tumors were the only biomarkers used to test for ovarian cancer. That is okay when you have big masses of tumors, but it is not applicable in very early phases of the tumor. Testing the proteins produced by the body in response to the presence of the tumor as well as the proteins the tumors produce, helped us to create a unique picture that can detect early ovarian cancer.

Mor and colleagues have begun a phase III evaluation in a multi-center clinical trial. In collaboration with EDRN/NCI and Laboratories Corporation of America (LabCorp), they are testing close to 2,000 patients.

The test is available at Yale through the Discovery to Cure program. Yale has licensed the test to three companies: Lab Corp in the United States, Teva in Israel and SurExam in China.


'/>"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
Source:Eurekalert  

Related medicine news :

1. Test Detects Sensitivity to HIV Drug
2. McMaster test detects the most prevalent respiratory viruses
3. CT colonography detects wide-range of extracolonic abnormalities in elderly patients
4. Blood protein detects lung cancer, even at earliest stage
5. New technique detects specific chromosomal damage, may indicate lung cancer risk
6. New Survey Suggests Confusion, Lack of Awareness About Heart Failure Could Be Preventing Critical Early Detection and Treatment
7. JCI online early table of contents: Feb. 7, 2008
8. New study suggests link between environmental toxins and early onset puberty in girls
9. A Reminder to Parents: Early Dental Visits Essential to Childrens Health
10. Rheumatoid arthritis sends many into early retirement
11. Early detection critical in treating pediatric thyroid cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Yale test detects early stage ovarian cancer with 99 percent accuracy
(Date:1/24/2017)... Texas (PRWEB) , ... January 24, 2017 , ... ... year introduces more changes during the Annual Enrollment Period (AEP) and the Open ... scrambling looking for health insurance coverage. Mainly, people are witnessing higher deductibles, rising ...
(Date:1/24/2017)... ... 2017 , ... Manzo Pharmaceuticals, LLC., announced that the name ... the United States Patent and Trademark Office. The purpose of this is ... thinking that other products are similar to the patented Lacto-Freedom Probiotic. ...
(Date:1/24/2017)... ... January 24, 2017 , ... Seceon , ... threats in real-time, today announced a strategic partnership with Paramount , the ... respond and protect their critical information assets and infrastructure, in a comprehensive and ...
(Date:1/24/2017)... , ... January 24, 2017 , ... Bellus Medical, a ... team of medical experts. In his new role Dr. Dobke will provide physician oversight ... Dr. Dobke is the Head of Plastic Surgery and Associate Professor of Surgery at ...
(Date:1/24/2017)... ... , ... The University of Iowa, long recognized as one of the top ... provides teachers with the specific skills and training they need to teach English as ... students and HigherEducation.com is working to ensure that this new program is available to ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... India , Jan. 24, 2017 Market Research Future ... Integumentary System Market. The global market for Plastic Surgery & Integumentary ... by the end of the forecasted period. Market Highlights ... Global Plastic Surgery ... market and predicted that the market will reach high growth figures ...
(Date:1/24/2017)... , Jan. 24, 2017 Regeneron Pharmaceuticals, Inc. ... Public today recognized 40 finalists in the Regeneron Science ... and math competition for high school seniors. Finalists were ... of their research projects. The finalists will ... from March 9-15 to undergo a rigorous judging process ...
(Date:1/24/2017)... LONDON , January 24, 2017 Analysis ... End User Liquid Biopsies - our new study reveals ... biopsy market heading? If you are involved in this sector you ... you the potential revenues streams to 2027, assessing data, trends, opportunities ... ...
Breaking Medicine Technology: